Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...

Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer: Los Angeles Thursday, July 17, 2025, 15:00 Hrs [IST] Kairos Pharma, Ltd., a clini ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th ...

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on the phase 2 trial.

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...

LOS ANGELES, CA, USA I July 15 2025 I Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer ...

Stay up-to-date on Kairos Pharma, Ltd. Common Stock (KAPA) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.

The event will take place on Aug. 5 at 6 p.m. at the Port Wentworth Fire Department Headquarters, located at 100 Anchor Park ...

ASX bounced back with banks in charge, Aussie jobs data missed, and now all eyes are on a possible August RBA rate cut.

The S&P/ASX 200 hit its 10th record high of the year, rallying 0.90% to close at best levels. Here's what you need to know ...